120 related articles for article (PubMed ID: 87046)
1. Cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in advanced gastrointestinal cancer.
Scanni A; Tomirotti M; Margulis A; Biraghi M; Curtarelli G
Tumori; 1979 Feb; 65(1):111-7. PubMed ID: 87046
[TBL] [Abstract][Full Text] [Related]
2. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
[TBL] [Abstract][Full Text] [Related]
3. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
Ackland SP; Anton A; Breitbach GP; Colajori E; Tursi JM; Delfino C; Efremidis A; Ezzat A; Fittipaldo A; Kolaric K; Lopez M; Viaro D;
J Clin Oncol; 2001 Feb; 19(4):943-53. PubMed ID: 11181656
[TBL] [Abstract][Full Text] [Related]
4. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Buser KS; Joss RA; Piquet D; Aapro MS; Cavalli F; Haefliger JM; Jungi WF; Bauer J; Obrist R; Brunner KW
Ann Oncol; 1993 Jun; 4(6):475-9. PubMed ID: 8353089
[TBL] [Abstract][Full Text] [Related]
5. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
Shapiro CL; Gelman RS; Hayes DF; Osteen R; Obando A; Canellos GP; Frei E; Henderson IC
J Natl Cancer Inst; 1993 May; 85(10):812-7. PubMed ID: 8487326
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study.
Cocconi G; De Lisi V; Boni C; Mori P; Malacarne P; Amadori D; Giovanelli E
Cancer; 1983 Feb; 51(4):581-8. PubMed ID: 6336981
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial.
Muss HB; Howard V; Richards F; White DR; Jackson DV; Cooper MR; Stuart JJ; Resnick MI; Brodkin R; Spurr CL
Cancer; 1981 Apr; 47(8):1949-53. PubMed ID: 7194733
[TBL] [Abstract][Full Text] [Related]
8. [Primary chemotherapy of metastatic breast carcinoma with bendamustine hydrochloride, methotrexate and fluorouracil versus cyclophosphamide, methotrexate and fluorouracil].
Ruffert K
Zentralbl Chir; 1998; 123 Suppl 5():156-8. PubMed ID: 10063603
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone, 5-fluorouracil, and high dose leucovorin (NFL) versus intravenous cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in first-line chemotherapy for patients with metastatic breast carcinoma: a randomized phase II trial.
Hainsworth JD; Jolivet J; Birch R; Hopkins LG; Greco FA
Cancer; 1997 Feb; 79(4):740-8. PubMed ID: 9024712
[TBL] [Abstract][Full Text] [Related]
10. Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Wilcox PM; Fetting JH; Nettesheim KM; Abeloff MD
Cancer Treat Rep; 1982 Aug; 66(8):1601-4. PubMed ID: 7049385
[TBL] [Abstract][Full Text] [Related]
11. Correlation of estrogen receptors and response to chemotherapy of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in advanced breast cancer.
Chang JC; Wergowske G
Cancer; 1981 Dec; 48(11):2503-6. PubMed ID: 7296498
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
Wozniak AJ; Blumenstein BA; Crawford ED; Boileau M; Rivkin SE; Fletcher WS
Cancer; 1993 Jun; 71(12):3975-8. PubMed ID: 8508363
[TBL] [Abstract][Full Text] [Related]
13. "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).
Engelsman E; Klijn JC; Rubens RD; Wildiers J; Beex LV; Nooij MA; Rotmensz N; Sylvester R
Eur J Cancer; 1991; 27(8):966-70. PubMed ID: 1832904
[TBL] [Abstract][Full Text] [Related]
14. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
Fisher B; Dignam J; Mamounas EP; Costantino JP; Wickerham DL; Redmond C; Wolmark N; Dimitrov NV; Bowman DM; Glass AG; Atkins JN; Abramson N; Sutherland CM; Aron BS; Margolese RG
J Clin Oncol; 1996 Jul; 14(7):1982-92. PubMed ID: 8683228
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of cyclophosphamide, methotrexate, and 5-fluorouracil with or without estrogenic recruitment in women with metastatic breast cancer.
Ingle JN; Foley JF; Mailliard JA; Krook JE; Hartmann LC; Jung SH; Veeder MH; Gesme DH; Hatfield AK; Goldberg RM
Cancer; 1994 May; 73(9):2337-43. PubMed ID: 8168039
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
De Lena M; Brambilla C; Morabito A; Bonadonna G
Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
[TBL] [Abstract][Full Text] [Related]
18. [Combination chemotherapy with cyclophosphamide, methotrexate, 5-fluoro-uracil, and vincristine in solid metastasized tumours (author's transl)].
Castor H; Fritsch H; Drings P; Moskwa G; von Kaick G
Med Klin; 1974 Apr; 69(17):750-6. PubMed ID: 4837493
[No Abstract] [Full Text] [Related]
19. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
[TBL] [Abstract][Full Text] [Related]
20. Dose intensity of chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil in the elderly with advanced breast cancer.
Beex LV; Hermus AR; Pieters GF; van Hoesel QG; Nooy MA; Mignolet F
Eur J Cancer; 1992; 28(2-3):686-90. PubMed ID: 1591094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
